13th week of 2012 patent applcation highlights part 38 |
Patent application number | Title | Published |
20120076729 | METHODS OF TREATING CANCERS - The present application describes methods for treating and/or preventing cancer or a cancer symptom, e.g., AMPK-related cancers, in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an FGF, e.g., FGF21, or an FGF agonist, or a pharmaceutical composition comprising the same. | 2012-03-29 |
20120076730 | PEPTIDES FOR TRANSPORT OF THERAPEUTICS AND THEIR CARRIERS IN MOUSE MODELS AND HUMANS - A system for targeted delivery of agents (e.g., molecular probes, diagnostic agents, therapeutic agents, imaging agents, research or analytical compounds, enzymes, peptides, proteins, lipids, lipoproteins, sugars, hormones, vitamins, nucleic acids, viruses, bacteria, and/or cells) including use of a composition containing the agent and a targeting moiety, specific for a determinant at the target location. An exemplary composition of the system includes a targeting moiety of one of peptides γ3, 2γ3, 3γ3, A1, B7, B8, B9, B1O, and D6, specific for targeting ICAM-I. The system enables effective, versatile, and safe targeting and transport of agents. The system is useful in research applications, as well as in the context of translational science and clinical interventions. | 2012-03-29 |
20120076731 | Lymphedema associated genes and model - The present invention identifies genes whose gene products are differentially expressed in lymphedema tissues, particularly cutaneous tissue involved in whole organ response to lymphedema. The invention provides methods for diagnosing or assessing an individual's susceptibility to lymphedema. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lymphedema. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have or at risk of developing lymphedema. | 2012-03-29 |
20120076732 | PHOSPHODIESTERASE INHIBITORS AND USES THEREOF - The invention provides for compounds that are phosphodiesterase inhibitors. The invention further provides for a method for screening compounds that bind to and modulate a phosphosdiesterase protein. The invention also provides methods for treating conditions associated with accumulated amyloid-beta peptide deposit accumulations by administering a phosphodiesterase-binding compound to a subject. | 2012-03-29 |
20120076733 | POST-BIOPSY CAVITY TREATMENT IMPLANTS AND METHODS - A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture. | 2012-03-29 |
20120076734 | RADIOPAQUE ANTIBIOTIC DENTAL PASTE AND USES THEREOF - Compositions useful for disinfecting a dental wound are described. The compositions include an active ingredient comprising one or more antibiotics, a radiopaque substance, and optionally a pharmaceutically acceptable excipient. Methods for treating dental wound sites with the compositions are also described. | 2012-03-29 |
20120076735 | Nanoparticles for Extravascular Administration - Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and/or diagnostic agents, for use in research and medical applications. | 2012-03-29 |
20120076736 | HOST SUPPORTED GENETIC BIOSENSORS - The present invention relates to an in vivo method of monitoring an analyte in a subject. This method involves providing an expression vector that encodes a biosensor molecule, the biosensor molecule comprising an analyte binding domain and a signal domain. The biosensor molecule produces a signal from the signal domain upon binding of the analyte by the analyte binding domain. The signal is detectable by a non-invasive means. The expression vector is introduced locally into in vivo cells of a subject under conditions effective to express the biosensor molecule in the cells. The signal from the expressed biosensor molecule is detected by a non-invasive means, thereby monitoring the analyte in the subject in vivo. | 2012-03-29 |
20120076737 | METHOD OF USING CT/MRI DUAL MODALITY CONTRAST AGENT - Nanoparticles are used as a contrast agent for magnetic resonance imaging and computed tomography. Each of the nanoparticles includes a metal alloy core and a plurality of hydrophilic molecules covalently bound to the surface of the metal alloy core. Also disclosed is a method for using the contrast agent. | 2012-03-29 |
20120076738 | COMBINATION TREATMENT FOR DERMATOLOGICAL CONDITIONS - The invention relates to a method of treating dermatological conditions or symptoms associated therewith in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the affected area of skin on the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier. | 2012-03-29 |
20120076739 | Novel combination of anticholinergics-b2-adrenoceptor agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids and/or phosphodiesterase 4 inhibitors for the treatment of inflammatory diseases - The invention relates to novel combinations based on anticholinergics, β | 2012-03-29 |
20120076740 | WATER SOLUBLE PHARMACEUTICAL COMPOSITIONS OF HOPS RESINS - The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions can also be dissolved in water to yield a clear solution containing more dilute hops acids. The invention also provides methods of treatment comprising administering water-soluble hops compositions. The present invention is also drawn to methods for making water-soluble preparations of hops constituents. | 2012-03-29 |
20120076741 | Sunscreen Composite Particles for UVA and UVB Protection - Sunscreen composite particles for UVA and UVB protection are described. The particles are substantially free of supplied UVB sunscreen and are prepared with a UVA sunscreen suitable to undergo keto-enol tautomerization. | 2012-03-29 |
20120076742 | Topical drug delivery system with dual carriers - A topical drug delivery system for use as a self-medication delivery system, formed as a multi-functional hygroscopic solution comprising a non-hygroscopic first chemical penetration enhancer, a hygroscopic second chemical penetration enhancer and an anti-oxidizing dispersant mixable in solution with the first and second chemical penetration enhancers and an active pharmaceutical ingredient, said dispersant being in a weight percent of the solution of between 3% and 10% and being suitable for providing multiple secondary therapeutic effects by interaction with the active pharmaceutical ingredient to ensure substantial homogenous distribution of the selected active pharmaceutical ingredient in the solution during delivery of the solution to all areas of the mammalian tissue location and by further reducing the water activity level of the solution. | 2012-03-29 |
20120076743 | NOVEL ARYL C-XYLOSIDE COMPOUNDS, AND COSMETIC USE - The present invention relates to novel compounds of formula (I) | 2012-03-29 |
20120076744 | UNSATURATED FATTY ACID MONOESTERS AND DIESTERS ON ASCORBIC ACID AND COSMETIC USES THEREOF - The present invention relates to a compound with the following general formula (I): | 2012-03-29 |
20120076745 | HAIR COSMETIC PRODUCT - A hair cosmetic product has a two agent type hair cosmetic which comprises a first agent containing an alkali agent and a second agent containing hydrogen peroxide, wherein at least one of the first and second agents contains a surfactant; and a foamer vessel which discharges a mixed liquid comprising the first and second agents in the form of foam. Another hair cosmetic product has a two agent type hair cosmetic which contains a first agent that includes an alkali agent and a second agent that includes hydrogen peroxide, and which is used after mixing the first and second agents immediately prior to use, and a foamer vessel from which a mixed liquid of the first and second agents is discharged in the form of foam. A surfactant is contained in the mixed liquid at an amount of 0.1 to 10 wt %, and the viscosity of the mixed liquid at 25° C. is 1 to 300 mPa·s. | 2012-03-29 |
20120076746 | HAIRSPRAY - A hairspray which contains (A) to (C):
| 2012-03-29 |
20120076747 | CATIONIC SYNTHETIC POLYMERS WITH IMPROVED SOLUBILITY AND PERFORMANCE IN PHOSPHATE SURFACTANT-BASED SYSTEMS AND USE IN PERSONAL CARE AND HOUSEHOLD APPLICATIONS - The present invention is related to surfactant-based formulations comprising the polyelectrolytes and blends of such polyelectrolytes with non-cellulosic cationic polysaccharide polymers wherein the surfactant is a phosphate ester. The surfactant-based formulations exhibit improved clarity of the resulting formulations, their improved conditioning of keratin substrates, textile substrates, and hard-surface substrates, their improved deposition of dispersed phase materials onto keratin substrates, textile substrates, and hard-surface substrates, their improved lather performance, and their improved rheology in applications such as personal care and household care products and textile applications. | 2012-03-29 |
20120076748 | Odor conjugater for chemically neutralizing odors - An odor conjugater for chemically neutralizing odors. | 2012-03-29 |
20120076749 | Modified Blood Factors Comprising a Low Degree of Water Soluble Polymer - The present invention relates, in general, to materials and methods for the preparation of modified blood factors which have low levels of water soluble polymer molecules conjugated to the blood factor but exhibit biological activity similar to or better than molecules having a higher number of water soluble polymer moieties. | 2012-03-29 |
20120076750 | FIBRIN BASED GLUE WITH FUNCTIONALIZED HYDROPHILIC POLYMER PROTEIN BINDING AGENT - The present invention provides a non-liquid biomaterial that may be used as a surgical sealant, a suture support, a blood flow controller, an adhesion reducing agent, an adhesion preventing agent, a tissue support, a tissue filler, a wound dressing or a combination thereof. The non-liquid biomaterial may comprise a blood derived material such as plasma, platelet poor plasma, platelet rich plasma or a material derived from blood containing tissue aspirate, such as bone marrow aspirate, a protein binding agent and a polymerizing agent. Methods for making and using the non-liquid biomaterial are also provided. | 2012-03-29 |
20120076751 | PLANT VOLATILES - The present invention provides compounds and compositions for attracting or repelling sap-sucking insects, such as whitefly, as well as methods for using such compositions. | 2012-03-29 |
20120076752 | Mesothelin Vaccines and Model Systems - Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line. | 2012-03-29 |
20120076753 | USE OF NKP46 FOR PREVENTING DIABETES - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes. | 2012-03-29 |
20120076754 | Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis - The present invention relates to the prevention or treatment of atherosclerosis, using an IL-17 polypeptide and pharmaceutical compositions thereof. | 2012-03-29 |
20120076755 | Hepatitis C Virus Inhibitors - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2012-03-29 |
20120076756 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2012-03-29 |
20120076757 | COMPOSITION FOR TRANSMUCOSAL DELIVERY OF POLYPEPTIDES - The invention described herein provides an oral solid transmucosal dosage form that enhances transmucosal permeation of biologically active polypeptides across oral mucosal tissue and provides relatively rapid efficacious therapeutic onset thereof. Dosage forms prepared according to the invention can enhance transmucosal absorption of polypeptides in therapeutic serum concentrations to the recipient. The invention provides a solid dosage form for oral transmucosal absorption of a biologically active polypeptide, wherein the dosage form comprises a pharmaceutical composition comprising: a therapeutically active polypeptide; a bile salt; and an effervescent excipient component, which can comprise an effervescent couple and optionally a pH adjusting substance. The invention includes a method of administering a biologically active polypeptide, as well as a method of enhancing transmucosal absorption of a biologically active polypeptide. | 2012-03-29 |
20120076758 | ANTIBODIES AGAINST WEST NILE VIRUS AND THERAPEUTIC AND PROPHYLACTIC USES THEREOF - The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV), infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions. | 2012-03-29 |
20120076759 | TRANSPLANTATION OF BONE MARROW STROMAL CELLS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS). | 2012-03-29 |
20120076760 | COMPOSITIONS AND METHODS OF VASCULAR INJURY REPAIR CROSS-REFERENCE TO RELATED APPLICATIONS - The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium. | 2012-03-29 |
20120076761 | Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including Parkinson's disease - Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease. | 2012-03-29 |
20120076762 | INDUCED PLURIPOTENT STEM CELL GENERATION USING TWO FACTORS AND P53 INACTIVATION - Methods and compositions are provided for, inter alia, the generation of induced pluripotent stem cells. Induced pluripotent stem cells may be generated by reprogramming and inhibition of p53. Further, useful intermediates for the generation of induced pluripotent stem cells are also provided. | 2012-03-29 |
20120076763 | COMBINATION ANTI-HIV VECTORS, TARGETING VECTORS, AND METHODS OF USE - Recombinant lentiviral vectors containing at least: a lentiviral backbone comprising essential lentiviral sequences for integration into a target cell genome; a nucleic acid encoding a CCR5 RNAi; and an expression control element that regulates expression of the nucleic acid encoding the CCR5 RNAi element, are provided by this invention. In an alternative aspect, the vector also contains polynucleotides encoding TRIMS alpha and HIV TAR decoy sequences along with gene expression regulation elements such as promoters operatively linked to the polynucleotides. The vectors are combined with packaging plasmid and envelope plasmids and optionally conjugated to cell-specific targeting antibodies. Diagnostic and therapeutic methods for using the compositions are further provided herein. | 2012-03-29 |
20120076764 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS - A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected by administering the composition to a wound. | 2012-03-29 |
20120076765 | Use of Novel Strains for Biological Control of Pink Rot Infections in Potato Tubers - Six bacterial strains: | 2012-03-29 |
20120076766 | Topical drug delivery system with dual carriers - A method of selecting the constituent elements of a therapeutic composition for application to wounds having a pathogen load is disclosed. The method includes selecting a pharmaceutical active agent selected from a list of pharmaceutical active agents approved for over the counter non-prescription use, and said pharmaceutical active agent having suitable activity to kill the desired pathogens; identifying a tissue permeation enhancer from a list of generally recognized and safe tissue permeation enhancers that facilitates penetration of a composition using the selected tissue permeation enhancer through the stratum corneum of mammalian tissue; selecting a hygroscopic carrier agent suitable for mixing in solution with the tissue permeation enhancer and the pharmaceutical active agent; said hygroscopic carrier agent being selected from a list of generally recognized and safe hygroscopic carrier agents; and ensuring that the activity/water (A | 2012-03-29 |
20120076767 | PROCESS FOR CONCENTRATION OF A POLYPEPTIDE - The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such a concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection. | 2012-03-29 |
20120076768 | DIGESTIVE/LAXATIVE COMPOSITIONS - Described are digestive/laxative compositions and methods of manufacture and use of same. In a preferred embodiment, the invention provides for a digestive/laxative composition including actinidin. The actinidin is preferably contributed by inclusion of fruit of genus | 2012-03-29 |
20120076769 | HERBAL COMPOSITION FOR CANCER TREATMENT - A therapeutic herbal composition comprising Saw Palmetto, Bromelain, Willow Herb, Grape Seed Complex, Wild Rosella, Liquorice, Passionfruit Seed and Selenium Yeast is claimed. The composition may be used as a general health promotant but is also useful as a treatment of cancer and inflammation. Prostate cancer and hyperplasia may be particularly beneficially addressed with the composition. The invention extends to a method of treatment using a composition as described. | 2012-03-29 |
20120076770 | Modulation of autophagy and and serotonin for treatment of multiple myeloma related diseases - THE INVENTION RELATES TO compounds, proteins and methods of treatment therewith. Aspects of embodiments of the invention further relates to compounds and methods of treatment for bone, bone marrow, and bone tissue. | 2012-03-29 |
20120076771 | SURFACE MODIFICATION OF SILK FIBROIN MATRICES WITH POLY(ETHYLENE GLYCOL) USEFUL AS ANTI-ADHESION BARRIERS AND ANTI-THROMBOTIC MATERIALS - The present invention provides compositions and methods for the production of silk fibroin matrices surface-PEGylated on one or more surfaces. Such surface-PEGylated silk fibroin matrices can be used in biomedical applications, such as anti-adhesive and anti-thrombosis materials. Silk matrices may be surface-PEGylated, for example, by a reaction with a functional group-activated PEG. Controlling the degree of PEGylation on surface of silk fibroin matrix can regulate both the degradation rate of the silk matrix, and the differentiated adhesion of cells or differentiated adsorption of proteins on the surface of the silk matrix. The present invention also provides for silk fibroin matrices having one or more surfaces possessing differentiated adhesion properties, which allows for tissue integration on the adherent side and inhibition of tissue adhesion to the opposing tissues or organs. Embedding active agents in silk fibroin matrices provides more benefits, such as promoting tissue ingrowth on the adherent side of the matrix. | 2012-03-29 |
20120076772 | STABILIZATION OF IMMUNOGLOBULINS THROUGH AQUEOUS FORMULATION WITH HISTIDINE AT WEAK ACIDIC TO NEUTRAL PH - The present invention provides, among other aspects, storage stabile aqueous formulations of immunoglobulins with histidine at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing immunoglobulin compositions by formulating with histidine at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stabile aqueous compositions of immunoglobulins at mildly acidic to neutral pH useful for parenteral administration. | 2012-03-29 |
20120076773 | Novel Drug Delivery Devices - Compositions provided by contacting a biotin-containing component and an avidin-containing component are useful as drug delivery devices. Bioactive agents may be covalently bound to the biotin-containing component, the avidin-containing component, or both, mixed therewith, or combinations of the foregoing. | 2012-03-29 |
20120076774 | DETECTION AND/OR TREATMENT OF DISEASES ASSOCIATED WITH AUTOANTIBODIES - The present invention provides a method for detecting autoantibodies to osteoprotegerin (OPG). The method comprises the step of providing a biological sample from a subject with, or at risk of osteoporosis and detecting whether or not any antibodies against osteoprotegerin (OPG) are present in said sample. In addition the invention provides methods useful in aiding the diagnosis/prognosis and/or therapeutic regimen for autoimmune and/or vascular disease in general. | 2012-03-29 |
20120076775 | Combination of HGF Inhibitor and EGF Inhibitor to Treat Cancer - The present invention is directed toward a method of treating cancer by administering to a patient an inhibitor of Hepatocyte Growth Factor and an inhibitor of, e.g., Epidermal Growth Factor. | 2012-03-29 |
20120076776 | METHOD FOR TREATING INFLAMATION BY LYMPHOCYTE DEPLETION OR SEQUESTERING - A method for preventing inflammation, comprising administering to a subject a lymphocyte sequestrating or depletion agent before the onset of inflammation. A method for treating inflammation caused by an injury or an infection, comprising depleting immune lymphocyte of a subject by administering to said subject a lymphocyte sequestrating or depletion agent during or after said event. A method for preventing or treating abdominal adhesion comprising administering to a subject a lymphocyte sequestering or a lymphocyte depletion agent. | 2012-03-29 |
20120076777 | ANTI-FIBROBLASTIC FLUOROCHEMICAL EMULSION THERAPIES - The present invention is directed to compositions and methods targeting tissue resident cells, such as fibroblasts, in a subject harboring conditions or at risk for conditions that would benefit from anti-fibroblastic therapy. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent delivered in combination with the fluorochemical composition. | 2012-03-29 |
20120076778 | Antibodies Against Insulin-Like Growth Factor I Receptor and Uses Thereof - An antibody binding to IGF-IR and being glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is between 20% and 50%, has improved properties in antitumor therapy. | 2012-03-29 |
20120076779 | STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph - The present invention provides, among other aspects, storage stabile aqueous formulations of labile proteins at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing a labile therapeutic protein composition at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stabile aqueous compositions of labile proteins at mildly acidic to neutral pH useful for parenteral administration. | 2012-03-29 |
20120076780 | RECOMBINANT FUSION PROTEIN AND POLYNUCLEOTIDE CONSTRUCT FOR IMMUNOTOXIN PRODUCTION - The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of | 2012-03-29 |
20120076781 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES - One aspect of the invention provides methods for treating cancers which are resistant to treatment with a protein tyrosine kinase inhibitor by co-treatment with the protein tyrosine kinase inhibitor and one or more antisense oligomers that reduce the expression of HER3 and/or HER2 and/or EGFR. Another aspect of the invention provides methods for treating cancers by co-treatment with an inhibitor of HER2 and one or more antisense oligomers that reduce the expression of HER3. | 2012-03-29 |
20120076782 | GENERATION AND PROFILING OF FULLY HUMAN HUCAL GOLD.RTM.-DERIVED THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38 - The present invention provides novel methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma. | 2012-03-29 |
20120076783 | REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS - The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations. | 2012-03-29 |
20120076784 | HIGHLY CONCENTRATED, LIQUID FORMULATIONS OF ANTI-EGFR ANTIBODIES - The invention relates to processes for the preparation of highly concentrated, liquid formulations comprising at least one anti-EGFR antibody and/or one of its variants and/or fragments, in particular monoclonal antibodies against the EGF receptor, particularly preferably of Mab C225 (cetuximab) and Mab h425 (EMD 72000), by ultrafiltration. The invention furthermore relates to highly concentrated, liquid formulations of anti-EGFR antibodies, in particular of monoclonal antibodies against the EGF receptor, particularly preferably Mab C225 (cetuximab) and Mab h425 (EMD 72000) and/or variants and/or fragments thereof, characterised in that the highly concentrated, liquid formulations have a content of anti-EGFR antibodies of 10-250, preferably 50-180 mg/ml, particularly preferably of 100-150 mg/ml, and to the use thereof. | 2012-03-29 |
20120076785 | METHOD FOR INHIBITING NEURODEGENERATION - Methods for screening for compounds that inhibit neurodegeneration are presented. Shedding of APP can be a useful marker for neurodegeneration and compounds that inhibit shedding of APP are useful as inhibitors of neurodegeneration. Such compounds may be useful in treatment and/or prevention of various neurological diseases, disorders and neuronal damage and may enhance growth, regeneration or survival of mammalian neuronal cells or tissue. | 2012-03-29 |
20120076786 | BISPECIFIC ANTIBODIES - The present invention provides compositions and methods for targeting stem cells to injured cardiac tissue. | 2012-03-29 |
20120076787 | COMBINATION OF A TNF-ALPHA ANTAGONIST AND A VEGF ANTAGONIST FOR USE IN THE TREATMENT OR PREVENTION OF DISEASES OF THE EYE - The invention relates to combinations of TNFα antagonists with VEGF antagonists for use in treating diseases of the eye, and provides antigen-binding proteins which bind to TNFα or a TNFα receptor and/or VEGF or a VEGF receptor. | 2012-03-29 |
20120076788 | C-CBL AND ANTAGONISTS THEREOF FOR THE TREATMENT AND DIAGNOSIS OF CANCER - The present invention relates to the treatment of cancer. More specifically, the present invention relates to the use of c-cbl as a marker for the diagnosis and/or prognosis of cancer, and to the use of a c-cbl antagonist for the treatment of a cancer associated with resistance to apoptosis. | 2012-03-29 |
20120076789 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 121P1F1 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene (designated 121P1F1) and its encoded protein, and variants thereof, are described wherein 121P1F1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 121P1F1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 121P1F1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 121P1F1 can be used in active or passive immunization. | 2012-03-29 |
20120076790 | ANTI-CD48 ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to CD48 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human CD48. In certain embodiments, the antibodies of the present invention block the binding of CD48 to one or more CD48 receptor. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more CD48 biological activities, including the treatment of allergic conditions and other inflammatory conditions. | 2012-03-29 |
20120076791 | Methods Of Treating Chronic Prostatitis/Chronic Pelvic Pain Syndrome - The present invention relates to the use of TNF-α for the treatment of a pain and/or a urinary tract symptom(s) associated with Cronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS). | 2012-03-29 |
20120076792 | ANTIBODY SELECTIVE FOR A TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR AND USES THEREOF - An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of o the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth. | 2012-03-29 |
20120076793 | AGENT FOR PROMOTING HEPATIC CELL REPLICATION AND AGENT FOR IMPROVING INSULIN RESISTANCE - The present invention aims at providing a medicament and a method for promoting replication of hepatocytes and a medicament and a method for ameliorating insulin resistance. | 2012-03-29 |
20120076794 | Host cell specific binding molecules capable of neutralizing viruses and uses thereof - Provided are human binding molecules that specifically bind to a host cell protein and have virus neutralizing activity, nucleic acid molecules encoding such human binding molecules, compositions comprising the human binding molecules, and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of viral infections. | 2012-03-29 |
20120076795 | Anti-PECAM Therapy, Compositions, Methods, and Uses - The disclosure relates to the discovery that systemic administration of an antibody that binds to PECAM-1 increases body weight while suppressing the metastatic spread of a wide variety of different tumor types which are typically fatal in humans. This discovery provides a basis for the generation of novel treatments and medicaments, wherein provision of a systemic dosage of anti-pECAM-1 antibody or a proxy that provides the same functional result is administered to a patient suffering from cancer cachexia and/or metastasis associated with end-stage cancer | 2012-03-29 |
20120076796 | AMINO ACID SEQUENCES DIRECTED AGAINST THE ANGIOPOIETIN/TIE SYSTEM AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF DISEASES AND DISORDERS RELATED TO ANGIOGENESIS - The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl12, Angptl13, Angptl14, Angptl15, Angptl16, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences. | 2012-03-29 |
20120076797 | Modulation of kit signaling and hematopoietic cell development by IL-4 receptor modulation - Methods and compositions are provided for modulating Kit/stem cell factor receptor (SCFR)/CD117 and interleukin 4 receptor (IL-4R) signaling in a cell in vitro and in vivo, and for identifying candidate agents with activity in modulating Kit and IL-4R signaling. These methods find particular use in treating disorders of the hematopoietic system and in modulating hematopoietic stem cell expansion. | 2012-03-29 |
20120076798 | Antagonistic Human LIGHT-Specific Human Monoclonal Antibodies - Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental. | 2012-03-29 |
20120076799 | ANTAGONISTS OF PCSK9 - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 2012-03-29 |
20120076800 | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations of Antibodies - The present invention relates to non-aqueous high concentration reduced viscosity suspension formulations of antibodies and methods of making and using them. | 2012-03-29 |
20120076801 | HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease. | 2012-03-29 |
20120076802 | HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF - The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease. | 2012-03-29 |
20120076803 | ANTIBODIES TO TROPONIN I AND METHODS OF USE THEREOF - The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome. | 2012-03-29 |
20120076804 | CANCER TARGETED INNATE IMMUNITY - Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual. | 2012-03-29 |
20120076805 | Methods and Compositions for the Generation and Maintenance of Regulatory T Cells - Methods and compositions for generating and maintaining induced regulatory T cells (iTregs) are provided. Methods and compositions for treating an autoimmune disorder, organ transplant rejection, graft versus host disease or allergic or hypersensitivity and inflammation are also provided. | 2012-03-29 |
20120076806 | Chloramphenicol Acetyl Transferase (CAT)-Defective Somatostatin Fusion Protein And Uses Thereof - Chimeric somatostatin-based polypeptides, polynucleotides used to encode the polypeptides, the methods for isolating and producing the polypeptides and the uses thereof are provided. In addition, low cost adjuvants for enhanced immunogenic response are provided. Vaccinations that include both chimeric somatostatin-based polypeptides and novel adjuvants are included, useful in facilitating farm animal productivity. | 2012-03-29 |
20120076807 | PLASMIDS WITH IMMUNOLOGICAL ACTION - Recombinant plasmids usable for the transfection of eukaryotic and prokaryotic cells are described; such plasmids have a length comprised between 7 and 12 kbases and comprise a sequence encoding the heavy chain of an immunoglobulin; in particular, they may be used:
| 2012-03-29 |
20120076808 | COMBINED ANTIGEN AND DNA VACCINE FOR PREVENTING AND TREATING AUTOIMMUNE DISEASES - The present invention relates to treating and preventing symptoms of an allergy, asthma, an autoimmune disease, and transplant rejection using a combination vaccine containing an antigen and a DNA encoding the antigen. | 2012-03-29 |
20120076809 | METHOD TO INHIBIT THE BIOLOGICAL ACTIVITY OF CALCINEURIN WITH SELECTIVE PEPTIDES - The invention relates to the biotechnology sector involving the area of human health. More specifically, the invention is based on the surprising usefulness of peptides LxVPc1, c3 and c4 as efficient selective inhibitors of the calcineurin signalling pathway (CN)-NFAT and the phosphate activity of CN. Said compounds are useful immunosuppressors and serve as a base for the preparation of therapeutic compositions for the prophylactics and treatment of human diseases associated with T-lymphocyte activation, including, but not limited to, autoimmune diseases, inflammation and allergy or transplant rejections. In addition, said peptides and the associated biological and genetic material can form useful tools for the development of tests that can be used to find compounds that have a selective antagonist activity in relation to CN. | 2012-03-29 |
20120076810 | VACCINIA VIRUS POLYPEPTIDES - This document provides methods and materials related to polypeptides present in a vaccinia virus (e.g., polypeptides that can be isolated from naturally processed and presented class I polypeptides originating from vaccinia virus, a member of the Orthopoxvirus family). For example, methods for generating a vaccine comprising one or more of vaccinia virus polypeptides disclosed herein for preventing or treating Orthopoxvirus infection are provided. In addition, kits related to the use of vaccinia polypeptides are provided. | 2012-03-29 |
20120076811 | IMMUNODOMINANT COMPOSITIONS AND METHODS OF USE THEREFOR - The present invention relates to immunodominant compositions, including immunodominant peptides of HA1 of influenza H5 hemagglutinin, polynucleotides encoding such peptides, and their methods of use. Such peptides are useful, for example, for the prevention, treatment and diagnosis of influenza. | 2012-03-29 |
20120076812 | ANTIVIRAL VACCINES WITH IMPROVED CELLULAR IMMUNOGENICITY - The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects. | 2012-03-29 |
20120076813 | USES OF GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS - The present invention relates to polypeptide fragments, including variants and analogs, of | 2012-03-29 |
20120076814 | COMBINATIONS OF PNEUMOCOCCAL RRGB CLADES - Pneumococcal pilus subunit RrgB has at least three clades. Serum raised against a given clade is active against pneumococci which express that RrgB clade, but is not active against strains which express one of the other two clades i.e. there is intra-clade cross-protection, but not inter-clade cross-protection. Thus an immunogenic composition can include at least two different clades of RrgB to improve strain coverage against pilus-containing pneumococci. These multiple clades may be present in the immunogenic composition as separate polypeptides or may be fused as a single polypeptide chain. | 2012-03-29 |
20120076815 | IDENTIFICATION AND CHARACTERIZATION OF RACEMASES, DEFINITION OF PROTEIN SIGNATURES, AND A TEST FOR DETECTING D-AMINO ACID AND FOR SCREENING MOLECULES CAPABLE OF INHIBITING THE ACTIVITY OF RACEMASE, ESPECIALLY PROLINE RACEMASE - This invention provides identification and characterization of racemases and definition of protein signatures of these racemases. This invention also provides identification of nucleic acid molecules encoding a peptide consisting of a motif characteristic of the protein signatures, and to the peptides consisting of these motifs. Antibodies specific for the peptides and to immune complexes of these antibodies with the peptides are also provided. Further, the invention relates to methods and kits for detecting racemases using the nucleic acid molecules of the invention, as well as the peptides consisting of the motifs and antibodies to these peptides. | 2012-03-29 |
20120076816 | NOVEL MALARIA VACCINE - The present invention provides a vaccine for preventing and/or treating | 2012-03-29 |
20120076817 | POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES - Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products. | 2012-03-29 |
20120076818 | IMMUNOGENIC COMPOSITION AND USE THEREOF - The invention relates to an immunogenic composition comprising an adenoviral vector and a pox viral vector, or two different adenoviral vectors, wherein one or more of the vectors encodes one or more target antigens; and related methods, uses and kits. | 2012-03-29 |
20120076819 | Compositions And Methods For Treating of Microbial Infections - The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions. | 2012-03-29 |
20120076820 | CD40L VACCINES, COMPOSITIONS, AND METHODS RELATED THERETO - The disclosure relates to vaccinating a subject against a viral infection, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the use of CD40L expressed on viral like particle as an adjuvant, in combination with a viral antigen, to vaccinate a subject. | 2012-03-29 |
20120076821 | ANTIGENIC CHIMERIC TICK-BORNE ENCEPHALITIS VIRUS/DENGUE VIRUS TYPE 4 RECOMBINANT VIRUSES - Disclosed herein are chimeric TBEV/DEN4 flaviviruses including a first nucleic acid molecule including a 5′ non-coding region (NCR) from a DEN4 virus, a nucleic acid encoding a C protein and non-structural proteins from a DEN4 virus, and a 3′ NCR from a DEN4 virus, wherein nonstructural protein NS4B includes a phenylalanine at amino acid position 112, nonstructural protein NS5 includes an alanine at amino acid position 654 and an alanine at amino acid position 655, and the 3′ NCR includes a deletion of nucleotides 10478-10507. The chimeric construct also includes a second nucleic acid molecule, which is operably linked to the first nucleic acid molecule, encoding a prM protein and an E protein from a TBEV, wherein the E protein includes an amino acid substitution that differs from the wild type TBEV at amino acid position 315 and a tryptophan at amino acid position 240. Also disclosed are methods of eliciting an immune response using the disclosed TBEV/DEN4 chimeric flaviviruses and immunogenic compositions including the disclosed chimeric flaviviruses and a pharmaceutically acceptable carrier. | 2012-03-29 |
20120076822 | INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE - Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 μg/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains. | 2012-03-29 |
20120076823 | Vector - The present invention relates to a herpes virus vector which comprises a modified genomic sequence encoding a microRNA (miRNA) against a target sequence. The herpes virus vector may be used as or in a vaccine to prevent and/or treat a disease. | 2012-03-29 |
20120076824 | NOVEL EDWARDSIELLA ICTALURI E-ICT-VL33 STRAIN, VACCINES THEREOF, AND A METHOD FOR PROTECTING FISHES USING SAID VACCINES | 2012-03-29 |
20120076825 | PHARMACEUTICAL PRODUCT COMPRISING MITE ALLERGEN EXTRACT(S) AND A METHOD FOR THE MANUFACTURE THEREOF - The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f). | 2012-03-29 |
20120076826 | Recombinantly Produced Allergens - The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy. | 2012-03-29 |
20120076827 | Compositions and methods for generating an immune response in a subject - The invention relates to a method for providing an activated antigen-presenting cell or a composition that comprises at least one activated antigen-presenting cell, which method at last comprises the steps of providing a composition that comprises at least one antigen-presenting cell and contacting said composition with a vaccine. Suitably, the at least one dendritic cell is brought into a state in which it is capable of stimulating T-cells and/or a T-cell mediated response. | 2012-03-29 |
20120076828 | KANAMYCIN ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF CANCER - The invention relates to a nucleic acid comprising a sequence complementary to a fragment of the sequence coding for the kanamycin resistance protein. This nucleic acid is useful as a DNA vaccine adjuvant, and can be used e.g. for treating cancer, for example in combination with a non-immunosuppressive inducer of tumor cell apoptosis such as all-trans retinoic acid (ATRA). | 2012-03-29 |